Abstract

This paper outlines the arguments and counterarguments within the scientific communities on the issue of common genetic factors discovered in mental disorders. The main objective of the research is to analyse the relationship between genetics and mental health. The relevance of this study by FAAVM Canada, (North America), is to help recognize that major mental health disorders share certain genetic defects. These findings may also point to apply better multidisciplinary scientific research methodologies to diagnose and treat these conditions. However, genetic factors can increase the risks of mental health issues, or make us more vulnerable to developing them, by reducing the brain’s ability to deal with or compensate for traumas and other cognitive disruptions. This research empirically confirms and theoretically proves that the results can be useful for vaccine and pharmaceutical drug development. Across the European Union (EU) region, approximately 165 million people are affected annually by mental illnesses, for the most part, anxiety, mood, and substance abuse disorders. On average, over 50% of the general population in middle-income and high-income countries will experience at least one mental illness at some point in their lives. That being said, mental illnesses are by no means limited to a minority group of predisposed persons but are a major public health challenge. These scientific attributes are in fact mandatory diagnostic criteria that exert considerable socio-economic repercussions not only for those affected but also for their families, communities, social, and employment related environments. In the first year of the Coronavirus (COVID-19) global pandemic, global frequency of anxiety and depression increased by an immense 25%, according to a scientific summary released by the World Health Organization (WHO). Mental illnesses and substance abuse disorders account for over 10.4% of the global burden of mental health diseases, owing to demographic changes and prolonged life expectancy, and were the leading cause of years lived with disability among all disease groups.

Keywords: socioeconomics, mental health, public health, scientific research, health, and wellbeing.

JEL Classification: I0, I14.

Cite as: Louis, R. (2022). The Global Socioeconomic Impact of Mental Health. SocioEconomic Challenges, 6(2), 50-56. https://doi.org/10.21272/sec.6(2).50-56.2022

This work is licensed under a Creative Commons Attribution 4.0 International License

References

1. Sebastian Trautmann, Jürgen Rehm, Hans‐Ulrich Wittchen (2016). The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? EMBO Rep., 17(9), 1245–1249. Published online 2016 Aug 4. [CrossRef].
2. Jani Nöthling, Stefanie Malan-Müller, Naeemah Abrahams, Sian Megan Joanna Hemmings, Soraya Seedat (2020). Epigenetic alterations associated with childhood trauma and adult mental health outcomes: A systematic review. World J Biol Psychiatry, 21(7), 493-512. [CrossRef].
3. Raphael Louis (2021). Music Therapy Positive Psychology Interventions. [CrossRef].
4. Charanraj Goud Alladi, Bruno Etain, Frank Bellivier, and Cynthia Marie-Claire (2018). DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder. Int J Mol Sci, 19(10), 3026. [CrossRef].
5. Chunyu Liu, Chuan Jiao, Kangli Wang, Ning Yuan (2018). DNA Methylation and Psychiatric Disorders. Prog Mol Biol Transl Sci, 157, 175-232. [CrossRef].
6. Carolyn Ptak, Arturas Petronis (2010). Epigenetic approaches to psychiatric disorders. Dialogues Clin Neurosci, 12(1), 25-35. [CrossRef].
7. Susana Gonzalo (2010). Epigenetic alterations in aging. J Appl Physiol, 109(2), 586-597. [Crossref].
8. Maria Shadrina, Elena A. Bondarenko, and Petr A. Slominsky (2018). Genetics Factors in Major Depression Disease. Front Psychiatry, 9, 334. [CrossRef].
9. Jennifer H. Barnett, Jordan W. Smoller (2009). The Genetics of Bipolar Disorder. Neuroscience, 164(1), 331-333. [CrossRef].
10. Muhammad Ummear Raza, Turan Tufan, Yan Wang, Christopher Hill, and Meng-Yang Zhu (2016). DNA damage in major psychiatric diseases. Neurotox Res, 30(2), 251–267. [CrossRef].
11. Phoebe Friesen, Ryan E. Lawrence, Gary Brucato, Ragy R. Girgis, Lisa Dixon (2016). Hopes and Expectations Regarding Genetic Testing for Schizophrenia Among Young Adults at Clinical High- Risk for Psychosis. J Psychiatr Pract, 22(6), 442–449. [CrossRef].
12. Abdullah Al Maruf, Mikayla Fan, Paul D. Arnold, J. Müller, Katherine J. Aitchison, Chad A. Bousman (2020). Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. Can J Psychiatry, 65(8), 521–530. [CrossRef].
13. F.S. Collins, L.D. Brooks, A. Chakravarti (1998). A DNA Polymorphism Discovery Resource for Research on Human Genetic Variation. Genome Res., 8, 1229-1231. [Link].
14. The World Health Organization (WHO) (2006). World Health Assembly adopts Comprehensive Mental Health Action Plan 2013–2020. Epidemiology and Psychiatric Sciences, 15(3), 161-166. [CrossRef].